Combination therapy of sodium–glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences

References

• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Eckerle Mize DL, Salehi M. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. Curr Diab Rep. 2013;13:307–318.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515–531.
   PubMed Web of Science ®Google Scholar
• Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249–1255.
   PubMed Web of Science ®Google Scholar
• Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2015;109(2):378–388.
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Maffioli P. Sitagliptin in type 2 diabetes mellitus: efficacy after five years of therapy. Pharmacol Res. 2015;100:127–134.
   PubMed Web of Science ®Google Scholar
• Geng J, Yu H, Mao Y, et al. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Pharmacoeconomics. 2015;33(6):581–597.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
   PubMed Web of Science ®Google Scholar
• Oliva RV, Bakris GL. Blood pressure effects of sodium–glucose co-transport2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8(5):330–339.
   PubMed Web of Science ®Google Scholar
• Del Prato S, Nauck M, Durán-Garcia S, et al., et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17(6):581–590.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
   PubMed Web of Science ®Google Scholar
• Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–514.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose co-transporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014;16(3):137–144.
   PubMed Web of Science ®Google Scholar
• Paquot N, Schneiter P, Jequier E, et al. Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects. Diabetologia. 1996;39:580–586.
   PubMed Web of Science ®Google Scholar
• Hansen L, Iqbal N, Ekholm E, et al. Postprandial dynamics of plasma glucose, insulin and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract. 2014;20:1187–1197.
   PubMed Web of Science ®Google Scholar
• Bollheimer LC, Landauer HC, Troll S, et al. Stimulatory short–term effects of free fatty acids on glucagon secretion at low to normal glucose concentrations. Metabolism. 2004;53:1443–1448.
   PubMed Web of Science ®Google Scholar
• Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512–517.
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI. Perspective: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;18:jc20151884. [Epub ahead of print].
   Google Scholar
• Singh AK. Sodium glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: wisdom of hindsight. Indian J Endocr Metab. 2015;19(6):722–730.
   PubMedGoogle Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEJM. 2015; [Epub ahead of print]. DOI:10.1056/NEJMoa1504720.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
   PubMed Web of Science ®Google Scholar
• Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730–1735.
   PubMed Web of Science ®Google Scholar
• Reimer RA, Grover GJ, Koetzner L, et al. Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese zucker rats. J Nutr. 2012;142(10):1812–1820.
   PubMed Web of Science ®Google Scholar
• Hansen HH, Hansen G, Paulsen S, et al. The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat. Eur J Pharmacol. 2014;741:254–263.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13(1):47–54.
   PubMed Web of Science ®Google Scholar
• Brand T, Macha S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther. 2012;29(10):889–899.
   PubMed Web of Science ®Google Scholar
• Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35(1):A33–42.
   PubMed Web of Science ®Google Scholar
• Chen L, Klein T, Leung PS. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med. 2012;12(8):995–1004.
   PubMed Web of Science ®Google Scholar
• Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP-4 inhibitors – from preclinical development to clinical research. Kidney Blood Press Res. 2012;36:65–84.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Mogensen CE, Schernthaner GH. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diabetes Vasc Dis Res. 2014;11:306–323.
   PubMed Web of Science ®Google Scholar
• Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study objective. Diabetes Care. 2014;37:740–750.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–383.
   PubMed Web of Science ®Google Scholar
• Matthaei S, Catrinoiu D, Celinski A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care. 2015;38:2018–2024.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38:2009–2017.
   PubMed Web of Science ®Google Scholar
• Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38(3):394–402.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393.
   PubMed Web of Science ®Google Scholar
• Woo V, Wysham C, Matheiu Cet al; Canagliflozin reduces both HbA1c and body weight in patients with type 2 diabetes on background dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 agonists. European Association of Study in Diabetes Meeting, Stockholm, Sweden; 2015: OP-31: P-186.
   Google Scholar
• Tanijawa Y, Kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose co-transporter 2, as monotherapy or in combination with other oral anti-diabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacol . 2014;15(6):749–766.
   PubMed Web of Science ®Google Scholar
• Seino Y, Inagaki N, Haneda M, et al Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest. 2015;6:443–453.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care. 2015;38:373–375.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Schernthaner-Reiter MH. How attractive is the combination of a sodium glucose co-transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes? Diabetes Obes Metabol. 2015;17:613–615.
   PubMed Web of Science ®Google Scholar
• Kramer CK, Zinman B, Choi H, et al. The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: Insight from the LIBRA trial. J Clin Endocrinol Metab. 2015;100(10):3702–3709.
   PubMed Web of Science ®Google Scholar